<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03573245</url>
  </required_header>
  <id_info>
    <org_study_id>ATX (Tranexamic acid )</org_study_id>
    <nct_id>NCT03573245</nct_id>
  </id_info>
  <brief_title>Tranexamic Acid in Major Orthopedic Surgery: Comparison of 3 Dosage Regimen</brief_title>
  <official_title>Tranexamic Acid in Major Orthopedic Surgery: Comparison of 3 Dosage Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CUF Santarém Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CUF Santarém Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tranexamic acid has been shown to be effective in reducing blood loss and transfusion in
      orthopedic surgery. It remains unknown the ideal therapeutic regimen. The goal of this study
      is to compare 3 dosage regimen of tranexamic acid in patients submitted to major orthopedic
      surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is ongoing debate, however, around optimal perioperative tranexamic acid dosing, which
      varies widely.

      A large number of studies comparing tranexamic acid to placebo, overall blood loss and
      transfusion requirements are both reduced by ≈30%. A well designed tranexamic acid trial will
      provide answers to the best regimen dosage for perioperative tranexamic acid use. It will
      benefit patients by reducing allogeneic transfusions and their associated risks and costs,
      thus adding value to the care delivered.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">July 1, 2018</start_date>
  <completion_date type="Anticipated">April 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Perioperative bleeding</measure>
    <time_frame>postoperative day 2</time_frame>
    <description>perioperative blood loss measured in mililiters (mL)</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Tranexamic Acid</condition>
  <condition>Knee Osteoarthritis</condition>
  <condition>Ankle Osteoarthritis</condition>
  <condition>Bleeding</condition>
  <arm_group>
    <arm_group_label>intra-op single dose</arm_group_label>
    <description>intra-operative single dose of tranexamic acid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intra-op dose and additional dose</arm_group_label>
    <description>intra-operative dose of tranexamic acid and additional dose 3 hours after</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intra-op dose and perfusion</arm_group_label>
    <description>intra-operative dose of tranexamic acid followed by a continuous infusion during 6 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>Tranexamic acid effect on perioperative bleeding in orthopedic surgery</description>
    <arm_group_label>intra-op dose and additional dose</arm_group_label>
    <arm_group_label>intra-op dose and perfusion</arm_group_label>
    <arm_group_label>intra-op single dose</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        • Patients of a median size private hospital in Portugal
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 anos

          -  Total ankle arthroplasty

          -  Total knee arthroplasty

          -  Weight &gt;50 kilogram

        Exclusion Criteria:

          -  Allergy and Hypersensitivity to tranexamic acid

          -  Thromboembolic events history

          -  Epilepsy

          -  Acute kidney injury, Glomerular Filtration Rate &lt; 50 ml/min

          -  Coagulation disorders

          -  Surgical reintervention

          -  Blood transfusion refusal
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angela Sa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CUF Santarem Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Angela Sa, MD</last_name>
    <phone>+351243240240</phone>
    <email>angela.sa@jmellosaude.pt</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vania Simoes, MD</last_name>
    <phone>+351243240240</phone>
    <email>vania.simoes@jmellosaude.pt</email>
  </overall_contact_backup>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>June 7, 2018</study_first_submitted>
  <study_first_submitted_qc>June 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2018</study_first_posted>
  <last_update_submitted>June 27, 2018</last_update_submitted>
  <last_update_submitted_qc>June 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>CUF Santarém Hospital</investigator_affiliation>
    <investigator_full_name>Angela Sa</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

